Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWIFT: Certolizumab Pegol in Rheumatoid Arthritis
NCT01292265Phase 3Terminated
- Sponsor
- UCB
- Start
- Feb 2011
- Primary completion
- Jan 2012
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 3 trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by UCB. Started Feb 2011; status: terminated.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01292265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01292265.